An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes.
Tsunosue
Miwako
M
Mashiko
Naomi
N
Ohta
Yhukou
Y
Matsuo
Yoshito
Y
Ueda
Kouichi
K
Ninomiya
Masayuki
M
Tanaka
Sho-ichi
S
Hoshiko
Masaru
M
Yoshiyama
Yasutsugu
Y
Takeuchi
Masayoshi
M
Ueda
Shin-ichiro
S
Yamagishi
Sho-ichi
S
D020909:Acarbose / Q000627:therapeutic use*; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D005985:Glyceraldehyde / Q000378:metabolism*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D044967:Serum / Q000737:chemistry
D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D065089:Glycoside Hydrolase Inhibitors; D005985:Glyceraldehyde; D020909:Acarbose